Keryx Biopharmaceuticals, Inc. (KERX) - Financial and Strategic SWOT Analysis Review

Date: May 24, 2016
Pages: 49
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: K32245A3B91EN
Leaflet:

Download PDF Leaflet

Keryx Biopharmaceuticals, Inc. (KERX) - Financial and Strategic SWOT Analysis Review
Keryx Biopharmaceuticals, Inc. (KERX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company which develops and commercializes innovative therapies for the treatment of renal disease. The company’s lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based compound. It has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through its Japanese partner Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. The company operates through its subsidiaries and also has its operational presence with its offices located in New York, and Boston in the US; the UK and Israel. Keryx is headquartered in New York, the US.

Keryx Biopharmaceuticals, Inc. Key Recent Developments

Apr 28, 2016: Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
Apr 01, 2016: Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors
Dec 10, 2015: Keryx Announces Appointment of John P. Butler to its Board of Directors
Oct 29, 2015: Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial Results
Aug 05, 2015: Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Keryx Biopharmaceuticals, Inc. - Key Facts
Keryx Biopharmaceuticals, Inc. - Key Employees
Keryx Biopharmaceuticals, Inc. - Key Employee Biographies
Keryx Biopharmaceuticals, Inc. - Major Products and Services
Keryx Biopharmaceuticals, Inc. - History
Keryx Biopharmaceuticals, Inc. - Company Statement
Keryx Biopharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Keryx Biopharmaceuticals, Inc. - Business Description
Keryx Biopharmaceuticals, Inc. - Corporate Strategy
Keryx Biopharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Keryx Biopharmaceuticals, Inc. - Strengths
Strength - Business Collaborations
Strength - Lead Product: Auryxia
Strength - Focused Research and Development Activities
Keryx Biopharmaceuticals, Inc. - Weaknesses
Weakness - History of Operating Losses
Keryx Biopharmaceuticals, Inc. - Opportunities
Opportunity - Medical Need for ESRD Patients
Opportunity - Strategic Expansion Initiatives
Opportunity - Changing Demographics
Keryx Biopharmaceuticals, Inc. - Threats
Threat - Competitive Pressures
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Keryx Biopharmaceuticals, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Keryx Biopharmaceuticals, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 28, 2016: Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
Apr 01, 2016: Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors
Dec 10, 2015: Keryx Announces Appointment of John P. Butler to its Board of Directors
Oct 29, 2015: Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial Results
Aug 05, 2015: Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
Jul 27, 2015: Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial Officer
May 04, 2015: Keryx Biopharmaceuticals Announces First Quarter 2015 Financial Results
Apr 30, 2015: Keryx Biopharmaceuticals Completes Transition Of Ceo Role To Greg Madison
Apr 23, 2015: Keryx Biopharmaceuticals Appoints John F. Neylan, MD, as Chief Medical Officer
Mar 10, 2015: Keryx Biopharmaceuticals Announces Appointment Of Greg Madison To Its Board Of Directors

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Keryx Biopharmaceuticals, Inc., Key Facts
Keryx Biopharmaceuticals, Inc., Key Employees
Keryx Biopharmaceuticals, Inc., Key Employee Biographies
Keryx Biopharmaceuticals, Inc., Major Products and Services
Keryx Biopharmaceuticals, Inc., History
Keryx Biopharmaceuticals, Inc., Subsidiaries
Keryx Biopharmaceuticals, Inc., Key Competitors
Keryx Biopharmaceuticals, Inc., Ratios based on current share price
Keryx Biopharmaceuticals, Inc., Annual Ratios
Keryx Biopharmaceuticals, Inc., Interim Ratios
Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Keryx Biopharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Keryx Biopharmaceuticals, Inc., Performance Chart (2011 - 2015)
Keryx Biopharmaceuticals, Inc., Ratio Charts
Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Keryx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Akebia Therapeutics, Inc.
Genzyme Corporation
Fresenius Medical Care AG & Co. KGaA
Onyx Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Skip to top


Ask Your Question

Keryx Biopharmaceuticals, Inc. (KERX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: